Onyx Lung Cancer Trial Fails

Xconomy San Francisco — 

Onyx Pharmaceuticals (NASDAQ: ONXX), the Emeryville, CA-based cancer drug developer, said today that sorafenib (Nexavar) failed to reach its main goal of helping people live longer with non-small cell lung cancer in a study of about 900 patients. The drug is currently marketed to treat kidney cancer, and a type of liver cancer known as hepatocellular carcinoma. The study unveiled today, called Nexus, evaluated people getting their first round of treatment for lung cancer. Onyx and Bayer have other studies ongoing against later stages of lung cancer.